NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹0.80 Cr | ₹0.80 Cr | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹0.80 Cr |
| Mar2025 | ₹0.80 Cr |
| Mar2024 | ₹0.44 Cr |
| Mar2023 | ₹0.10 Cr |
| Mar2022 | ₹0.28 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹0.80 Cr | 0.00 | |
| Mar2025 | ₹0.80 Cr | 80.95 | |
| Mar2024 | ₹0.44 Cr | 336.63 | |
| Mar2023 | ₹0.10 Cr | -63.67 | |
| Mar2022 | ₹0.28 Cr | - | |
Compare Contingent Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,921.9 Cr | 10.2% | 11.9% | 103.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,120.0 Cr | -3.2% | -7.8% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹253,390.0 Cr | -3.3% | -0.2% | 63.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,740.0 Cr | -2.4% | -5% | 33.6% | Stock Analytics | |
| CIPLA | ₹108,497.0 Cr | -4% | -5.6% | -10.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,925.0 Cr | -1.2% | 4.1% | -4.2% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 10.2% |
11.9% |
103.8% |
| SENSEX | -2.1% |
-5.9% |
-10.8% |
You may also like the below Video Courses